− Preliminary Data Show that Eltanexor is Well Tolerated and Demonstrates Promising Activity in Multiple Myeloma — − Expanding Program to Include Colorectal Cancer, Castration-resistant Prostate Cancer, and Myelodysplastic Syndrome — NEWTON, Mass., Dec.
− Data Provide Further Evidence of Tolerability with Robust Anti-Myeloma Activity When Selinexor is Combined with Velcade, Pomalyst, Revlimid or Darzalex — − SVd Arm Continues to Show High Response Rates, Including 83% ORR and >13-month PFS in BOSTON Patient Population; 63% ORR in the Overall Study
NEWTON, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2017 London Healthcare Conference on Thursday, November 16,
NEWTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November
− Company Completes Exclusive Licensing Transaction Valued at Up To $193 Million Plus Royalties with Ono Pharmaceutical Co. Ltd. for Selinexor and KPT-8602 In Japan and Certain Other Countries in Asia — − Michael Falvey Named Chief Financial Officer— − Fourteen Abstracts Selected for ASH 2017,
− ONO Rights Include Oncology Indications for Selinexor and KPT-8602 in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries — − Karyopharm to Receive ¥2.5 billion (US$22.3 Million) Upfront; Total Deal Value up to Approximately US$193.0 million with Karyopharm Eligible to Receive up to ¥19.15
— The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of 0.60 (RECIST v1.1), Representing a 40% Reduction in Risk of Progression or Death — — Phase 3 Portion of Study Commenced; Expanded to Include North America and Europe and Expected to Enroll Up To 222
— Michael Falvey, Formerly an Executive at Millennium Pharmaceuticals, Seven Bridges Genomics, Ahura Scientific, and Aspect Medical Systems, Brings 35 Years of Financial and Operational Experience at High Growth Companies — — Jatin Shah, MD, Formerly Associate Professor and Director of the Myeloma